Advances in “Bed and Bench” Research for Head and Neck Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1732
Special Issue Editors
Interests: head and neck cancer; HPV; EBV; immunotherapy; biomarker; cancer metabolism; novel therapeutic strategies; lipid; micro-RNA; quality of life; real-world evidence; epidemiology
2. Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung City, Taiwan
3. School of Traditional Chinese Medicine, Chang Gung University, Taoyuan City, Taiwan
Interests: head and neck cancer; immunotherapy; biomarker; cancer metabolism; novel therapeutic strategies
Special Issue Information
Dear Colleagues,
Head and neck cancer (HNC) is one of the most common malignant tumors with the characteristics of strong invasive ability, lymph node metastasis and high recurrence rate. In fact, despite recent advances in diagnosis and treatment, prognosis remains poor. A better understanding of the mechanisms involved in cancer behavior (“bench” studies) may lead to the identification of new potential therapeutic targets. Recent advances in clinical research that assesses the need for treatment strategies and new therapies also contribute to a better understanding of HNC-related quality of life and real-world evidence (“bed” studies).
This Special Issue aims to cover new insights from head and neck cancer "bed and bench" research, including big data analysis or multi-institutional cohort studies, molecular markers or omics profiling, etc. Original and review articles are welcome to enrich the literature and the scientific communities.
Dr. Sheng Dean Luo
Dr. Yu-Ming Wang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
